Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer

被引：0
|
作者：
Guang Ma
Shuhui You
Yizhao Xie
Bingxin Gu
Cheng Liu
Xichun Hu
Shaoli Song
Biyun wang
Zhongyi Yang
机构：
[1] Fudan University Shanghai Cancer Center,Department of Nuclear Medicine
[2] Shanghai Medical College,Department of Oncology
[3] Fudan University,Center for Biomedical Imaging
[4] Fudan University,Department of Breast Cancer and Urological Medical Oncology
[5] Shanghai Engineering Research Center of Molecular Imaging Probes,Department of Medical Oncology
[6] Fudan University Shanghai Cancer Center,undefined
[7] Zhongshan Hospital Fudan University,undefined
来源：
Cancer Imaging | / 23卷
关键词：
Heterogeneity of ; F-FDG uptake; Prognosis; Metastatic HER2 positive breast cancer; Dual target therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Pretreatment 18F- FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
    Ma, Guang
    You, Shuhui
    Xie, Yizhao
    Gu, Bingxin
    Liu, Cheng
    Hu, Xichun
    Song, Shaoli
    Wang, Biyun
    Yang, Zhongyi
    CANCER IMAGING, 2023, 23 (01)
  • [2] Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of 18F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
    Gong, Chengcheng
    Liu, Cheng
    Tao, Zhonghua
    Zhang, Jian
    Wang, Leiping
    Cao, Jun
    Zhao, Yannan
    Xie, Yizhao
    Hu, Xichun
    Yang, Zhongyi
    Wang, Biyun
    CANCERS, 2022, 14 (16)
  • [3] Pretreatment 18F-FDG uptake heterogeneity predicts response to pyrotinib in patients with metastatic HER2-positive breast cancer.
    Gong, Cc
    Liu, Cheng
    Tao, Zhonghua
    Zhang, Jian
    Wang, Leiping
    Cao, Jun
    Zhao, Yannan
    Li, Yi
    Xie, Yizhao
    Wang, Biyun
    Yang, Zhongyi
    Hu, Xichun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
    Aye, T. T.
    Mon, S.
    Khine, M.
    Sein, N.
    Thant, N. M.
    Win, A. K.
    Aung, E. P. P.
    Hnin, P. T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer
    Lee, Hee Jin
    Seo, An Na
    Kim, Eun Joo
    Jang, Min Hye
    Suh, Koung Jin
    Ryu, Han Suk
    Kim, Yu Jung
    Kim, Jee Hyun
    Im, Seock-Ah
    Gong, Gyungyub
    Jung, Kyung Hae
    Park, In Ae
    Park, So Yeon
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 142 (06) : 755 - 766
  • [6] Phase II trial of paclitaxel combined with trastuzumab and pertuzumab as preoperative therapy for HER2 positive inflammatory breast cancer
    Overmoyer, B. A.
    Regan, M.
    Brugge, J.
    Perou, C. M.
    Nakhlis, F.
    Jennifer, B.
    Heather, J.
    Eren, Y. D.
    Judith, H-B
    Winer, E.
    CANCER RESEARCH, 2013, 73
  • [7] A pilot study of pertuzumab, trastuzumab and eribulin for patients with advanced HER2 positive breast cancer
    Ishihara, M.
    Tamaru, S.
    Oda, H.
    Yamashita, Y.
    Tono, Y.
    Mizuno, T.
    Katayama, N.
    CANCER RESEARCH, 2016, 76
  • [8] The efficacy of trastuzumab, pertuzumab, and docetaxel in patients with HER-2-positive metastatic breast cancer
    Liem, Jean A.
    Kurniawan, Andree
    Christiano, Joysya
    Argo, Teresa M.
    Law, Natasha K.
    Asafia, Darlene
    ANNALS OF ONCOLOGY, 2022, 33 : S538 - S538
  • [9] SAFETY OF TRASTUZUMAB AND PERTUZUMAB FOR PATIENTS WITH PREVIOUSLY TREATED HER2 POSITIVE ADVANCED BREAST CANCER
    Sakaguchi, Haruna
    Ishihara, Mikiya
    Sawaki, Akihiko
    Nagaharu, Keiki
    Oda, Hiroyasu
    Sugawara, Yumiko
    Tamaru, Satoshi
    Yamashita, Yoshiki
    Mizuno, Toshiro
    Katayama, Naoyuki
    ANNALS OF ONCOLOGY, 2014, 25
  • [10] Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer
    Overmoyer, Beth
    Regan, Meredith
    Hu, Jiani
    Nakhlis, Faina
    Dominici, Laura
    Lin, Nancy U.
    Freedman, Rachel
    Morganstern, Daniel E.
    Partridge, Ann H.
    Schlosnagle, Emily J.
    Hirshfield-Bartek, Judi
    Bellon, Jennifer
    Morikawa, Aki
    Harrison, Beth T.
    Winer, Eric
    CANCER RESEARCH, 2018, 78 (04)
12345